Boehringer Ingelheim
News update from ASCO 2009: Ovarian cancer trial data BIBF 1120 (Vargatef ™)
Prof. Jonathan Ledermann,
Consultant Oncologist, UCL Cancer Trials Centre, London, UK
Latest news  play >
Download   vodcast  |  podcast
In-depth look   play >
Download   vodcast  |  podcast
News from ASCO 2009: BIBW 2992 (Tovok™)
Dr. James Spicer,
King's College London at Guy's Hospital, UK
Latest news  play >
Download   vodcast  |  podcast
In-depth look   play >
Download   vodcast  |  podcast

News from ASCO 2009: BIBF 1120 (Vargatef™)
Dr. Rolf Kaiser,
Boehringer Ingelheim, Germany
Latest news  play >
Download   vodcast  |  podcast
In-depth look   play >
Download   vodcast  |  podcast
Personalising Cancer Care Podcast RSS Personalising Cancer Care Podcasr RSS Webcast Help
Boehringer Ingelheim to Present New Phase II Clinical Data at ASCO 2009

Boehringer Ingelheim and DxS to develop diagnostic to identify lung cancer EGFR mutations
Mode of Action Animation
Probable or pipedream:
Could new cancer targets change the outlook for personalised medicine?
Oncology International Media Webcast Oncology International Media Webcast,
Chicago,
17 November 2008
PRESS RELEASE
First pivotal trials begin for Boehringer Ingelheim's novel triple angiokinase inhibitor BIBF 1120 (Vargatef™)
From

Message